Significant Benefits of Osimertinib against Adenosquamous Carcinoma Harboring Germline T790M Mutation.

CONCLUSION: Osimertinib can be a treatment option for patients with lung ASC harboring germline EGFR T790M mutation.
PMID: 32367600 [PubMed - as supplied by publisher]

Source: The Oncologist - May 3, 2020 Category: Cancer & Oncology Authors: Huo R, Li J, Li X, Shi J, Wang K, Jiao J, Shang Y Tags: Oncologist Source Type: research